AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

The average tax refund in 2024 was $3,138, which was similar to the $3,167 it averaged the previous year. While tax refunds ...

(RTTNews) - AbbVie Inc. (ABBV) Tuesday said that its Skyrizi approved for the treatment of adults with moderately to severely active ulcerative colitis is now available in Canada. Ulcerative ...

Under the leadership of Rob Michael, AbbVie continues to make tremendous progress in developing its immunology and ...

The company's cash payout ratio is about 47%, giving it plenty of room to grow its dividend. Here's the bottom line: Amgen is ...

ABBV’s Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for Humira in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to the ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...